MP-204

MP-204 is a best-in-class topical product in clinical development for the treatment of viral skin infections, such as anogenital warts caused by HPV, and has completed its Phase II clinical trial. MP-204 has shown significant results in the Phase 2 efficacy/safety study. The MP-204 formulation provides a shorter treatment duration (3 weeks), a better safety profile, higher patient compliance, and a higher level of complete recovery (over 90%) compared to the clinical data of the best alternative treatments.